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Summary.-This study analyses the activity of 95 antisera raised in rabbits against
human leukaemic myeloblasts. A number of different means were used to immunize
both normal rabbits and rabbits which had been treated to render them tolerant of
normal human splenic leucocytes. Different immunization schedules included the use
of different doses of untreated myeloblasts, as well as myeloblasts treated with neura-
minidase, antibody against human spleen cells or glutaraldehyde.
Analysis of the sera was carried out using two sensitive techniques for detecting
cell surface antigens: a radioactive anti-immunoglobulin binding assay using
1251-horse-F(ab')2-anti-rabbit-Fab and a K-cell-mediated cytotoxicity test using rat
spleen cells as effectors.
(i) The unabsorbed sera showed similar mean titres against leukaemic myeloblasts
and normal splenocytes.
(ii) Extensive absorption with pooled cadaveric spleen were required to remove
antibody against polymorphic antigens.
(iii) 17/95 antisera had activity against at least some leukaemic myeloblasts after
extensive absorption with cadaveric spleen.
(iv) Some ofthe 17 absorbed sera with selective activity for myeloblasts also reacted
against PHA-induced lymphoblasts.
(v) Although the 17 absorbed sera showed little or no activity against marrow in
the above assays normal human marrow totally absorbed all residual activity in
these sera against leukaemic myeloblasts.
We conclude that although these sera contain activity against antigens common to
leukaemic myeloblasts and a minority population of normal marrow cells, they have
no detectable activity against leukaemia-specific antigens.
DESPITE much circumstantial evidence
for their presence, the existence of human
tumour-specific antigens remains a tenta-
tive proposition. Nevertheless, over the
years there have been several reports of
the production of heterologous antisera
specific for leukaemia-associated antigens
in acute myeloblastic leukaemia (AML)
and other leukaemias (Garb et al., 1962;
Hyde et al., 1967; Mann et al., 1971; Mann
et al., 1974; Metzgar et al., 1972; Mohana-
kumar et al., 1974; Baker et al., 1974;
Durantez et al., 1976). In addition,
stimulation of lymphocyte blastogenesis
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by leukaemic cells, particularly in the
autologous situation (Fridman and Kouril-
sky, 1969; Viza et al., 1969; Powles et al.,
1971; Taylor et al., 1976) and in HL-A-
identical siblings (Fefer et al., 1976) has
been presented as evidence for the exis-
tence of these antigens. These findings
have generated much interest in the
possibility of exploiting these leukaemia
antigens in active immunotherapy to
prolong the duration of clinical remission
in AML (Powles et al., 1973; Freeman et
al., 1973; Powles et al., 1977).
Recently, HL-A D-locus antigens com-L. TIUPCHONGx AND I. C. M. MACLENNAN
monly associated with B-cells (Ia antigens)
(Arbeit et al., 1975; Mann et al., 1975a)
have been reported on the surface of a
high proportion of acute leukaemia cells
(Fu et al., 1975; Schlossmann et al., 1976;
Billing et al., 1976, 1977). It is clear that
several antisera which were previously
reported to be specific for leukaemia are,
in fact, directed against these antigens
(Billing et al., 1976; Zighelboim et al.,
1977). Furthermore, the stimulation of
atutologous and HL-A-identical peripheral
blood lymphocytes by leukaemic cells
may be related to the presence of these
antigens on leukaemic cells (Opelz et al.,
1977). Autologous MLC stimulation by
normal lymphocyte subpopulations occurs
in analogous conditions with a high
T-cell-responding cell population and a
B-cell-enriched stimulating population
(Lohrmann et al., 1974; Opelz et al., 1975;
Kuntz et al., 1976) and antisera against Ia
antigens inhibit these reactions (Cresswell
and (Geier, 1975).
In this report we describe attempts to
confirm the presence of leukaemia-speci-
fic antigens, by producing rabbit antisera
against human leukaemic myeloblasts by
a variety of techniques. The specificities
of the heterologous antisera produced
against AML have been analysed by 2
sensitive techniques, a K-cell-mediated
cytotoxicity test and a non-cytotoxic
radio-immune anti-immunoglobulin bind-
ing technique. The results suggest that
the surface antigenic make-up of leukae-
mic myeloblasts is qualitatively normal.
The antigenic determinants present on
leukaemic myeloblasts include those wlhich
are characteristic for a minority popula-
tion of normal marrow cells. There is also
evidence for antibodies in these AML
antisera which are reactive with PHA-
stimulated lymphoblasts and which can-
not be absorbed out by splenic lymphoid
cells. If leukaemia-specific antigens com-
mon to most patients with AML exist,
they are either non-immunogenic in the
animals studied or are below the resolution
of the tests used for their detection in this
study.
METHODS AND MATERIALS
Patients. These w%ere adults admitted to
the Radcliffe Infirmary, Oxford, which was
one of the centres involved in the recent
British Medical Research Council's 6th AML
Immunotherapy Trial. The diagnosis of
acute myeloblastic leukaemia (AML) was
made on cliiiical grounds, and on conventional
morplhological criteria and cytochemistry
wAith Sudan Black B, PAS and Romanovsky
stains (Hayhoe et al., 1964). Patients were
selected for study only if they had at least
90°(U myeloblasts in the peripheral blood.
Collection and storage of myeloblasts.-
Blood w-as taken into heparin or acid-citrate
dextrose from each patient at clinical
presentation before chemotherapy Awas in-
stituted. Myeloblasts w-ere separated from
peripheral blood and marrow aspirates by
Ficoll-Triosil gradient centrifugation (Boyum,
1968) or after the sedimentation of blood
under 1 g and the removal of the leucocyte-
rich plasma. The cells wrere washed twice in
pre-heated normal saline (37°C) to remove
free plasma and passively carried proteins
and then resuspended in RPMI 1640 (Gibco-
Biocult,Paisley) whichwassupplementedwith
10% foetal calf serum, 1% non-essential
amino acids, 2 mm fresh glutamine, penicillin
and streptomycin. Dimethyl sulphoxide was
added to the cell suspension to a final
concentration of 10%. The cells were then
rapidly dispensed into polycarbonate am-
poules (Sterilin, Surrey) and then cooled at
1-2°C/min until the temperature had been
lowNered to - 60°C. The ampoules were
then stored over liquid N2.
The cells wNere thawed rapidly in a 37°C
waterbath and diluted gradually w-ith pre-
warmed normal saline + 10% FBS before
use. They were wAashed twice w-ith normal
saline. The viability of intact cells after
thawing, as assessed by trypan-blue dye
exclusion and phase microscopy was 70-9500.
Splenic lymphocytes.-Viable cells w%ere
obtained form normal spleens from patients
undergoing operation for acute splenic rup-
ture and stored by controlled-rate freezing.
Cadaveric spleens.-Macroscopically nornmal
cadaveric spleens were obtained within 48 h
of death from individuals who were free of
malignancy and overt infection, and were
stored at -20°C until used. The validity of
using spleens frozen at -20°C has been
extensively assessed with traumnatic spleens
used fresh and after being processed as cada-
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veric spleens. The absorptive capacity of
material prepared by these two techniques
could not be distinguished (Tupchong, 1978).
Before use, spleens were thawed at 370C,
homogenized in a moule (Mouli-baby grinder)
and thoroughly washed with phosphate-
buffered saline.
Marrow.-Fresh marrow cells were ob-
tained from ribs removed from patients
undergoing thoracotomy for non-malignant
conditions. As target cells, they were used
fresh or after storage in liquid N2 after
controlled-rate freezing. When used for
absorption purposes, they were lightly fixed
with glutaraldehyde (0-25%) (Avrameas and
Ternynck, 1969) and stored at 40C in 0.1%
sodium azide.
Remission lymphocytes.-Lymphocyteswere
isolated from defibrinated peripheral blood of
patients during clinical remission by centri-
fugation (400g) over a Ficoll-Triosil gradient
(sp.gr. 1-077) for 15 min at 22°C. The interface
contains 95% mononuclear cells, mainly
lymphocytes.
Production of antisera.-Antisera were
raised in rabbits from a variety of breeds,
including Blue, Chinchilla, Grey and New
Zealand White. A variety of immunological
procedures were used in attempts to improve
the specificity for tumour antigens (Table I):
(a) Untreated whole cells: Animals were
injected 2-3 times i.p. with washed
fresh or cryopreserved myeloblasts.
108 cells were normally used for each
injection, but in some rabbits either
106 or 109 cells were used in the primary
immunization. Injections were spaced
at 2-week intervals.
(b) Normal - antigen - blocking - serum
(NABS)-coated cells: NABS consisted of
a heat-inactivated pooled anti-lympho-
cytic and anti-marrow serum from 9
rabbits which had been immunized
with human splenic lvmphocytes or
fresh human marrow cells. Each rabbit
contributing to the pool received
cells from only one individual. Two
injections of 108 cells were given 14
days apart. The rabbits were bled on
Day 21. The dose of NABS required
to coat fully 108 myeloblasts was
calculated from a complement mediated
titration curve against 2 x 104 of
the relevant myeloblasts. Cryopreserved
myeloblasts were washed and then
resuspended in x 20 the volume cal-
culated. After 30 min, the cells were
injected i.p. together with the NABS.
This procedure was repeated for each
immunization. Injections of 108
NABS-treated cells were given i.p. on
Days 1 and 14 and the animals were
bled on Day 21-25.
(c) Neuraminidase-treated cells: Washed
myeloblasts were resuspendedin normal
saline at a concentration of 3 x 107
cells/ml. Vibrio cholerae neuraminidase
(Behringwerke AG Batch 1233 B, 25 or
50 i.u./3 x 107 cells) was added and
the mixture was incubated for 30 min at
37°C. The cells were then washed
twice in cold PBS, enumerated and
injected immediatelv.
(d) Gluteraldehyde-fixed cells: 0-25% glu-
taraldehyde (BDH) was added to
washed myeloblasts (at a concentration
of 107/ml) in normal saline. After 5 min
at room temperature, the cells were
washed x 3 in normal saline.
Induction of tolerance of human spleen cells.
-(1) Neonatal injection with human cells:
Neonatal rabbits were injected i.p. within 3 h
of birth with 1-2 x 108 human spleen cells
(carefully cryopreserved from ruptured
spleens). Injections were given daily for 12
daysandthenevery2daysfor aweek. In some
rabbits this was followed by twice-weekly
injections until 4 weeks after birth. When
rabbits were test-bled at one month ofage, all
had some antibody against splenocytes, and
the degree of tolerance achieved was in some
doubt. In further attempts to induce toler-
ance in these animals, cyclophosphamide
(Endoxana, Wellcome, Kent) (100 mg/kg)
was given i.p. together with 108 splenic
lymphocytes. In several rabbits (see Table I),
the cyclophosphamide was repeated either
alone or with splenic lymphocytes every
2 weeks. (ii) Neonatal injection with soluble
human antigen: Soluble human antigen was
prepared by 3M KCI extraction (Reisfeld
and Kahn, 1971) from 5 x 109 normal
splenic lymphocytes. The preparation was
ultracentrifuged at 160,000 g for 90 min and
the supernatant was tested for its ability to
inhibit the action of an anti-lymphocytic
serum against the original splenic lympho-
cytes as target cells. Neonatal rabbits were
injected i.p. daily with 10 mg of the soluble
extract for 10 days. They were test bled at
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one month and challenged with cyclophos-
phamide and normal splenic lymphocytes.
At this stage, none of the rabbits which
were injected with soluble material had
antibody against normal splenocytes. (iii)
Attempts to induce tolerance in adult
rabbits: Adult rabbits were injected i.p. at
3 months of age with cyclophosphamide
(100 mg/kg) together with 1-2 x 108 splenic
lymphocytes.
Irrespective of the method used to in-
duce tolerance, all rabbits were injected 14
days after the last injection of cyclophos-
phamide with 108 leukaemic myeloblasts
and this was repeated thrice at 14-day
intervals. In some animals, the immunizing
myeloblasts were coated with NABS prior to
injection.
Control antisera.-The following immune-
rabbit antisera were used as controls in the
absorptionprocedures: ananti-human-lymph-
ocyte serum, an anti-human-marrow serum,
an anti-C3H mouse L-strain-fibroblast serum
and an anti-C3H mouse benzopyrene-in-
duced-sarcoma serum.
Absorption of antisera.-Washed human
splenic homogenate and bone marrow cells
were used to remove activity against normal
tissue. The absorbing tissue was packed at
2200 g for 10 min and an equal volume of
antiserum was added. The mixture was re-
suspended and allowed to react for 1 h
at 4°C with frequent inversion. The anti-
serum was removed after centrifugation at
20,000 g for 10 min. No antiserum was
absorbed more than twice with the same
preparation of absorbing material.
Phytohaemagglutinin (PHA) stimulation of
lymphocytes.-Lymphocytes were suspended
in RPMI-1640-FBS at a concentration of
2 x 106 cells/ml and dispensed in 500 ,ul
aliquots into sterile 76 x 10 mm round-
bottomed plastic tubes (Sterilin, Middlesex).
Five hundred ,ul ofPHA (Wellcome Reagents,
Beckenham, Kent, Batch no. K.0979) diluted
6 parts in 1,000 with RPMI-FBS was added
to each tube. Unstimulated control tubes
received 500 u1l MEM only. All tubes were
then tightly capped and incubated at 37°C for
72 h. The stimulated and unstimulated
control tubes were each pulsed at the end of
68 h with 1 ,tCi (50 ,l) of [3H]TdR (Radio-
chemical Centre, Amersham). The unpulsed
PHA-stimulated cells were washed in medium
and used as target cells for testing the AML
antisera. The degree of stimulation was
determined by [3H]TdR uptake of an aliquot
of the stimulated cells using the technique
ofWaller and MacLennan (1977). The ratio of
counts in stimulated and unstimulated tubes
(stimulation index) varied between 12-6
and 20-0.
51Cr- labelling of cells.-Between 5 x 106
and 107 myeloblasts in 0 3 ml FBS were
labelled with 100 ,tCi sodium chromate
(Radiochemical Centre, Amersham, sp. act.
100-400 mCi/,ugCr) for 2 h at 37°C. For labell-
ing lymphocytes, 200-300 ,tCi of 51Cr was
used. After labelling, the cells were washed in
medium through a gradient of FBS carefully
layered at the bottom of the container.
The assays
K-cell-mediated cytotoxicity.-Heat-inacti-
vated antisera were serially diluted 1:3 in
100 ,u BME in Cooke microtitte plates.
Fifty microlitres of rat spleen cells from
Lewis rats (RSC, 6 x 107 cells/ml) were
added, followed by 50 pul 5Cr-labelled target
cells (4 x 105 cells/ml).
Controls consisted of (i) target cells, RSC
and medium without antibody (baseline
release-6 readings); (ii) target cells, RSC
and a known positive antiserum, diluted
1/20, which was at the plateau ofcytotoxicity.
The plates were sealed with non-toxic
adherent plastic film and incubated for 6 h at
37°C. They were then centrifuged at 200 g
for 5 min and 150 ,ul of the supernatant from
each well was transferred to small plastic
tubes for counting in an automatic Wallac
gamma-counter. Six tubes were also added
which contained the total activity added to
each well. The counts were processed accord-
ing to a programme designed to calculate
percentage actual 51Cr release, means, stan-
dard deviation and specific cytotoxicity
values. The following formulae were in-
corporated into the programme: percentage
actual 51Cr release:
(Supernatant aliquot ct/min x
1.33) - background > 100
total counts - background
Specific cytotoxicity:
(% release with test antibody -
% baseline release)
x 100
% release in positive control -
%baseline release
Mean duplicate assay values (percent
actual 51Cr release) were compared to mean
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baseline values (6 readings) for each dilution
of the antiserum and were considered signifi-
cantly different if:
mean assay value - 2 s.e.1 >
mean baseline value d- 2 s.e.2
where: s.e.1 = standard error of mean of
assay readings
e.2= standard error of mean of
baseline readings.
The lastdilution ofthe antiserumproducing
significant 51Cr release above baseline (P <
0.05) was taken as the end-point titre of the
antiserum. We are grateful to Dr G. T.
Warner for preparing the computer pro-
gramme.
'25Iodinated horse anti-rabbit (125I-HAR)
binding assay.-A horse anti-rabbit serum
(generous gift of Dr A. F. Williams, Depart-
ment of Biochemistry, Oxford) was purified
by elution from a Sepharose 4B immuno-
absorbent column (rabbit IgG), followed by
pepsin degradation. Pepsin (Sigma) was
added at 4 mg/100 mg protein for 20 h at
37°C in 01M sodium acetate buffer, pH 4*5.
The mixture was then passaged through a
Sephadex G200 filtration column. The F(ab')2
peak was taken and iodinated using a low
dose of chloramine T (BDH) (10-20 jug per
25 ,ug protein) using the technique of Jen-
senius and Williams (1974).
The assaywasperformedinround-bottomed
Cooke microtitre plates (Sterilin). To standard
3-fold dilutions of heat-inactivated anti-
serum in MEM was added live target cells
at , 5 x 105 cells per well. After preincuba-
tion of the antibody and target cells for 1 h
at 0-40C, the cells were washed x 3 with
PBS + 1% BSA and 0 02% azide. The
radio-labelled HAR antibody was then
added to the pelleted cells at 300,000-400,000
ct/min. The cells wereresuspended and left for
a further 60 min, after which they were
washed x 3. The final pellet was dissolved
in 100 ,ul NaOH (0*1M) and transferred to
small plastic tubes for gamma-counting.
RESULTS
General plan for assessing specificity of
antisera raised against leukaemic myelo-
blasts
Antisera were tested from 95 different
rabbits each immunized with leukaemic
myeloblasts from a single patient. Myelo-
blasts from 19 patients were used for
immunization. Several different immuni-
zation schedules were used, as well as a
variety of techniques to reduce the level
ofantibody against normal tissue antigens.
These immunization schedules are sum-
marized in Table I.
TABLE I.-Imnmunization schedules used to
raise rabbit AML antisera (see Methods)
No. of
Schedule antisera
Untreated whole cells* (wc)
106; 108
107; 108
108; 108; 108
109; 108
Normal-antigen-blocking serum (NABS)-
coated cells
Neuraminidase-treated cells (Neuram)
25 i.u./3 x 107 cells/ml + NABS
50 i.u./3 x 107 cells/ml
Glutaraldehyde-fixed cells
After tolerizing procedures:
neonatalinjectionwithsolublelymphocyte-
antigen
+ Cyt (x 2) with splenic cells
neonatal injection with whole cells
+ Cyt and splenic cells
+ Cyt (x 2) and splenic cells (x 2)
+ Cyt (x 2) and splenic cells
+ Cyt and splenic cells (x 2)
Adult tolerization:
Cyt and splenic cells
Cyt and splenic cells and NABS
5
5
31
4
6
5
4
4
9
1
9
2
1
3
1
5
* Immunizing doses are indicated in 2 or 3 suc-
cessive doses as shown.
t Cy = cyclophosphamide at 100 mg/kg/dose.
Before any absorption, the antisera were
testedfortheir capacity toinduce cytolysis
by rat spleen K-cells against a standard
testleukaemic-myeloblast preparation and
a test normal splenic-lymphocyte prepara-
tion. All antisera had strong activity
against both, with the mean end-point
titre against the myeloblasts ± 1 s.d.
being 38.12±1.24 and against the splenic
lymphocytes 37.58+1.96
The antisera were next passed throuLgh a
series of absorptions against pooled cada-
veric human spleen cells. Some sera were
also absorbed against erythrocytes and
platelets, but analysis of the absorptive
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capacity of these agents showed them to
be less efficient in this context than
splenocytes. Up to 8 absorptions with
cadaveric spleens were made on each
antiserum. The first 2 absorptions were
against an equal volume ofa single pool of
52 cadaveric spleens; absorption 3 was
against an equal volume of a further pool
of 50 spleens; absorption 4 against a pool
of 50 spleens; absorption 5 against 11
spleens; absorption 6 against 6 spleens;
absorption 7 against 21 spleens and
absorption 8 against 8 spleens. After the
second and subsequent absorptions, the
antisera were tested for K-cell cytotoxic
activity against at least two myeloblast
preparations (Myeloblast 2: HL-A A2,
AW32, BW35, BW40. Myeloblast 11:
HL-A Al, A3, B8, B17) and two splenic
lymphocyte preparations (ly 1: HL-A Al,
A2, B8, Ly 8: HL-A A2. A3, BW12,
BW35). Absorption proceeded until either
the antisera were positive against at least
one of the myeloblasts and negative
against the lymphocytes, or they were
negative against both. Seventeen of the
original antisera were found to be positive
against at least one of the myeloblasts,
while failing to induce K-cell-mediated
cytolysis against the lymphocytes. These
antisera then went forward for more
detailed analysis against a variety of
normal and leukaemic cells. At this stage
the 1251-anti-rabbit immunoglobulin assay
was also used. Finally, these 17 antisera
were absorbed against human marrow
TABLE II.-The K-cell-dependent antibody activity of AML antisera, which had been
absorbed twice with pooled cadaveric spleen, against 6 leukaemic myeloblast targets and
4 normal splenic lymphocyte targets
Target myeloblasts
My2 My6 My8 Myl3 Myl4
4 6 0 6 7
0 3 1 3 2
0 0 5 2 1
0 0 3 2 0
0 3 1 0 5
1 1 2 0 5
3 6 0 4 5
2 4 1 3 3
3 3 4 4 2
3 4 3 4 3
3 0 7 2 1
3 3 3 2 3
3 5 2 2 3
4 3 4 2 4
3 4 3 1 4
6 5 4 4 4
5 4 4 1 5
7 6 2 3 5
5 5 2 4 3
0 0 4 3 4
5 5 0 4 4
2 3 4 4 1
4 0 3 3 4
7 7 4 5 6
3 04 3-33 2-71 2-83 3-50
2-16 2-18 1-73 1-49 1-72
Target splenic
lymphocytes
Myl Ly5 Ly6 Ly7 Ly8
6 0 7 5 7
3 0 3 1 1
3 2 0 0 1
1 0 1 1 1
4 0 3 3 4
5 3 5 4 1
7 4 7 6 7
5 0 6 1 4
5 1 4 1 5
5 0 4 4 1
3 0 0 0 1
4 3 3 3 3
5 3 5 1 2
5 3 6 3 3
4 5 5 3 3
7 1 7 4 3
7 2 6 6 4
7 3 5 6 5
7 3 7 3 4
7 1 7 1 1
7 2 5 3 0
4 1 4 1 5
5 2 7 3 2
7 3 7 4 5
5-13 1-75 4-75 2-79 3-04
1-68 1-48 2-19 1-86 1-99
All antisera were tested against the same preparation ofeach target; i.e. target cells thawed and labelled as
a single batch. The activity represents the highest log3 K-cell-dependent antibody titre which produces
significant 51Cr release from target cells. The overall mean anti-AML titre was 3-42 ± 1-98; overall mean
anti-lymphocytic activity was 3-08 2-16. There is clearly no significant difference between anti-AML
and anti-lymphocyte titres.
* With Freund's complete adjuvant.
Serum
lab code
51
56
54
Hle
Pc
Pc2
61
Tr4
63
Pd3
44
Wlx
59
LI
L2
64
14
65
Hi
10
32
6
4
H6
Mean:
S.d.
Immunising
myeloblasts
My2
My2
My2
Myl5
Myl6
Myl6
My6
Myl7
My4
Myl
Myl
My9
Myl4
Myl8
Myl8
My4
Myl3
My6
Myl9
Myl
Myl
Myl
Myl
Myl9
Method
raised
WC
NABS
NABS
WC
WC
WC
WC
WC
NABS
Neuram
NABS
WC
WC
WC
WC
WC*
WC
Neuram
WC
WC
WC
WC
Neuram
WE
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FIG. 1. Original and residual activity against a leukaemic myeloblast preparation is shown for 3
antisera after double absorption with pooled cadaveric spleen (from 52 donors). The arrows indicate
the end-points (last antibody dilution producing statistically significant 51Cr release). The variable
loss ofdifferent antisera absorbed with the same absorbing preparation is shown .
. .absorbed x 2;
--- unabsorbed.
and retested against normal and leukaemic
cells.
Findings at the preliminary absorption
stage
Absorption against red blood cells
removed all anti-erythrocyte activity but
this was associated with the loss of no
more than one log3 K-cell-mediated anti-
body titre against lymphocytes or leukae-
mic myeloblasts.
Evidence of activity against polymorphic
antigens
After the first two absorptions with
spleen-cell pools, the sera were tested
against a panel of 6 leukaemic-myeloblast
preparations and 4 splenic-lymphocyte
preparations. The end-point K-cell-media-
ted antibody titres against these targets
is shown for 24 of the antisera at this
stage (Table II). It is clear from this
Table that some antisera do not react
against all targets, but all react well
against some of the targets. No target is
negative against all the antisera. This
finding is represented graphically for 3
antisera in Fig. 1. We interpret these
findings to indicate that the antisera have
significant activity against polymorphic
antigens on spleen cells and leukaemic
myeloblasts. Further evidence to support
this conclusion was derived from the
finding that antisera absorbed against a
single spleen-cell preparation, lost all
cytotoxic activity against the absorbing
spleen cells but not against allogeneic
spleen cells. Fig. 2 shows an example of
such an experiment. These experiments
indicate that species-specific antigens on
spleen cells are relatively easily absorbed.
Detailed analysis of antibody activity in
serafound to showselectivityforthescreening
myeloblasts used in the preliminary absorp-
tion stage
After the second and subsequent splenic
absorption stages, all sera were tested
against two myeloblast preparations (My2
andMyl1) and 2 lymphocyte preparations.
Seventeen antisera were found which
had no K-cell activity against the lympho-
cyte preparations, but which reacted
against at least one of the 2 myeloblast
preparations. Table III shows for these
17 antisera the mode of immunization,
the immunizing myeloblast and the num-
ber of absorptions required to remove
activity against the screening lympho-
cytes. The first detailed screen used for
these antisera was to test their ability to
60
50
40
30
20
10
0
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Absorbing spleen cells
2 4 6 8
Myeloblasts
2 4 6 8 0
Allogeneic spleen cells
-i-\
2 4 6
-2 log3x antibody dilution
FIG. 2.-Specificity for alloantigens on spleen cells by one AML antiserum. An AML antiserum,
absorbed with fresh spleen cells from one donor, showed residual activity against spleen cells from
a second donor and leukaemic myeloblasts from a third donor. -.-. -. before and --- after
absorption with spleen cells. Arrows indicate end-points for absorbed sera.
TABLE III.-Rabbit AML antisera, with residual activity against at least one of the 2
screening leukaemic myeloblasts after removal of activity against 2 splenic lymrphocytes
Serum lab code
4(5) 11/8
99
08
63 16/12
3(4) 1/10
59
35
79
65
32
09
19
44(5)
05
96
Wlcx
34
Immunising
myeloblast
Myl
My2
My3
My4
Myl
My5
Myl
My2
My6
Myl
My6
My2
Myl
My7
My8
My9
Myl
Method raised
(See Table I)
Neuram WC
Neuram + NABS
NTR
NABS
Neuram
Untreated
Untreated
TJntreated
Neuram
Untreated
NTR
NTR
NABS
NTR
Neuram + NABS
Untreated
Untreated
These AML+ antisera were selected for further testing. NTR = rabbits in
which induction of neonatal tolerance against normal human splenocytes was
attempted.
induce K-cell-mediated cytolysis against
panels of myeloblasts, lymphocytes, acute
lymphatic leukaemia cells, chronic lym-
phatic leukaemia cells and marrow cells.
The results of this screen are given in
Table IV, which shows that none of the
antisera was fully specific for myeloblasts
and, as in the preliminary screen, the
overall pattern strongly indicated marked
activity against polymorphic antigens.
It was felt to be impractical to proceed
to further absorption at this stage, and a
8n
70
60
50
40
.2
x,
0
.2
u
0L
LA
30
20
10
No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
No. of
absorptions
3
2
4
4
3
7
5
5
8
6
4
7
3
6
4
6
7
488
7
.\1
7
."%)-"..A -I489 SURFACE ANTIGENS IN AML
~~~~~~~~aq c e, '.4 0 = = t:3>- la 80 0
g t ; ~ ~ ~~~~~~~+ + + + + + d
Gt t V X _ _ > m s s s s b s- . o .R
; at cq _- cosssXs_ ssc c
0
¢ 0 -- ,XC
xo 00 -4 = C- m r -~ in 00 in 0 o _q -4 a 4o
co h- 1- e; c rsXsX se :o P
iz~~ ~~~~~~~ ~ m __z -- -, - ao °X°
m@u m + +~~~~~+ °+g
> _ > _ co X < N 0 w4 h,s
oo tt °P - 0C )X
co 00 - m m Iq 00 aq C4 l X O
Q-s, h- I' N --q
% )Wn
,; ~ ~~~~~~~~~ +DtgSX~(lct<s>xL. TUPCHONG AND I. C. M. MACLENNAN
TABLE V.-K-cell-mediated cytotoxic activity (as in Table IV) of selected AML+ antisera
against leukaemic myeloblasts, remission lymphocytes and remission bone marrow
from a single donor
Target
% Cr Release with
+ ve antibody
Baseline
release
Serum
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
*PHA-stimulated
Myeloblast blood lymphocytes
70 53
20
31+
18+
15+
15+
14+
14+
14+
13+
12+
11+
10+
9+
6+
6+
5+
4+
2+
33
27+
15+
5
21+
2
-11
35+
31+
8+
29+
20+
8+
7+
-2
-6
14+
0
Remissioi
blood
lymphocy
64
20
2
-6
-4
0
-11
-7
-6
7
11+
-1
5
15+
-9
17+
-9
-11
-11
n
Remission
tes marrow
53
11
13+
6
1
9+
3
3
7+
6+
1
5
8+
5+
6+
0
5+
1
2
1U
x
._
C)
6
4
2
n
I
Il
I!
I
A B C
Controls
1 2 3 4 5 6 7 8 9 10 11 12 13
Serum number
FIG. 3a.
14 15 16 17
FIG. 3a, b and c.-Binding ofabsorbed AML+ antisera to leukaemic myeloblasts and PHA-stimulated
remission cells from 3 donors, before and after absorption with normal bone marrow. The antisera
were tested against equal numbers of target myeloblasts and target remission cells in the same
experiment. * 0 activity against the myeloblasts; * O activity against the PHA-stimulated
remission cells; 0 * activity before the marrow absorption; 0 - - O activity after the marrow
absorption. The control antisera which had all been absorbed x 5 with cadaveric spleen were:
A: anti-lymphocytic antiserum. B: anti-marrow serum. C: anti-C3H mouse strain-L fibroblast.
Lines which are longer than the control antisera indicate increased specificity for the leukaemic
myeloblasts. In Fig. 3a these are shown by sera 1, 4, 6, 8, 11, 13 and 15 before absorption with
marrow, and serum 2 after absorption. In Fig. 3b, these are sera 1, 2, 4, 5, 6, 12, 14 and 16 before ab-
sorption and serum 6 also after absorption, but this is not seen against the myeloblasts of 3a and
3c. In Fig. 3c only sera 13 and 14 show increased activity against AML blasts before absorption.
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different approach was therefore adopted.
This was to test the antisera against
leukaemic myeloblasts, remission lympho-
cytes, PHA-stimulated lymphoblasts and
remission marrow cells, all from the same
donor. This was to avoid differences in
polymorphic antigens between leukaemic
and normal cells, although it might be
argued that the myeloblasts might possess
D locus antigens only expressed on a
minor fraction of the blood lymphocytes
and almost none on the lymphoblasts.
Results of a series of this type are shown
on Table V. A number of points emerge
from this experiment: (1) that sera 3, 5
and 6 induce significant K-cell-mediated
cytolysis against myeloblasts and not
against the non-leukaemic cells; (ii) that
several sera show activity against PHA-
stimulated lymphoblasts, but not against
lymphocytes; (iii) that marrow cells are
relatively unaffected by these antisera.
The effect of niarrow absorption
The last experiment described above
gives some indication that antibody might
exist in some of the sera which have
specificity, as assessed by K-cell-mediated
cytotoxicity, against leukaemic myelo-
blasts. Normal myeloblasts, however, are
a minority population in marrow and
cytotoxic assays on the whole marrow
might not detect activity against them.
Consequently, we subjected all 17 of the
sera to 2 absorptions against equal
volumes ofnormal marrow. Thisresulted in
complete loss of selective activity against
myeloblasts and PHA-stimulated remis-
sion lymphocytes from the same patient.
We concluded at this stage that the K-cell-
mediated cytotoxicity assay was detecting
specificity in these antisera which was
directed only against normal tissue anti-
gens.
The 1251-anti-immunoglobulin assay used
to assess the activity in the selected AML+
antisera
The same principle as used above (the
testing of myeloblasts in parallel with
PHA-stimulated lymphoblasts from the
same donor) was adopted for assessing
antisera with a radioactive anti-rabbit
immunoglobulin reagent (1251-HAR).
Three pairs of myeloblasts and autologous
lymphoblasts were tested for antigens
which bound the 17 antisera both before
and after double marrow absorption. The
results are shown in Fig. 3a, b and c. We
have drawn the following conclusions
from these experiments: (i) Many of the
sera before marrow absorption show
evidence of activity against myeloblasts,
andinsomecasesalso againstPHA-induced
lymphoblasts from one or 2 donors; (ii)
only Serum 13, and then only before
marrow absorption, shows clear evidence
for activity against an antigen present
on myeloblasts from all 3 donors; (iii) a
number of the sera show a greater differ-
ence between myeloblast and lympho-
blast counts before than after absorption
against normal marrow. This finding is
consistent with the presence ofdifferentia-
tion antigens characteristic of leukaemic
myeloblasts and of a minority population
in marrow; (iv) there is evidence for
polymorphism in these myeloid differen-
tiation antigens, in that the sera show a
varying degree of differential activity
between the 3 myloblast targets; (v)
there is little or no evidence of leukaemia-
specific activity.
DISCUSSION
Contrary to the reports of several other
workers (Mohanakumar et al., 1974; Mann
et al., 1974; Baker and Taub, 1973;
Durantez et al., 1976), our results do not
provide support for the concept of immu-
nogenic leukaemia-specific antigens in
AML. Despite the exhaustive testing of a
large number of heterologous antisera,
produced in a variety of ways, we have
not been able to develop an antiserum
which has potent activity against leukae-
mic myeloblasts but no significant activity
against normal tissues. Although the
AML titre of the antisera before absorp-
tion varied from 1/39,000 to 1/300,000, all
the activity could be removed by absorp-
tion with splenic lymphocytes and marrow
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cells. Splenic lymphocytes alone were
able to remove much of this activity,
indicating that common antigens between
lymphocytes and leukaemic myeloblasts
are responsible for most of the anti-AML
activity in the AML antisera. Fu et al.
(1975), Billing et al. (1976; 1977) reported
that a high proportion of undifferentiated
lymphoblastic and myeloblastic leukae-
mias react with antisera directed against
human Ia-like antigens. These HL-A D-
locus antigens are not present on normal
blood T cells or T blasts. Consequently,
assays with a high cut-off point for
cytotoxicity will find anti-Ia sera negative
for blood lymphocytes but positive for
most myeloid leukaemic cells. This might
explain much of the activity which was
present in previously reported anti-leu-
kaemic antisera. Similarly, antisera raised
with cells from B lymphoblastoid cell
lines (e.g. RAJI) (Mann et al., 1971; 1974;
1975b; Durantez et al., 1976) as well as
spontaneous anti-leukaemic antibody
found in normal individuals (Bias et al.,
1972; Cullen and Mason, 1976) might
be attributable to these antigens. Despite
the large number of reports suggesting
that leukaemia-specific antigens exist,
some investigators have failed to find
antibody specific for antigens found ex-
clusively on AML blasts, for example, in
human subjects undergoing active immu-
notherapy (Gale and MacLennan, 1977;
Klouda et al., 1975). Also, one worker
raising antisera against AML blasts
(Greaves, 1975) failed to confirm the
presence of tumour-specific antigens in
this disease.
Analysis of the AML antisera in this
study, therefore, reveals that they recog-
nize cell-surface antigens on leukaemic
myeloblasts which are essentially, if not
completely, equivalent to normal antigens
found on splenic lymphocytes and marrow
cells. This includes activity against human
alloantigens as well as against cell-cycle-
associated antigens present on PHA-
stimulated remission lymphocytes but
not on unstimulated cells. The increase in
reactivity against PHA-stimulated cells
was not explained by increased suscepti-
bility to cytotoxic lysis, since this activity
was also shown by the 125iodinated
anti-immunoglobulin assay. Only a small
fraction of the total activity of the
antisera was directed against putative
myeloid differentiation antigen, suggesting
that they may not be prominent on the
cell-surface of these cells.
Marrow was extremely effective in
removing residual activity (against both
leukaemic myeloblasts and PHA-induced
lymphoblasts) which remained after ab-
sorption with splenic lymphocytes. Spleen
cells were used because of the availability
of this tissue at post-mortem, and the
presence of a high proportion of B cells
expressing HL-A D-locus antigens and
mature myeloid cells. Because of the
heterogeneity of cells in marrow prepara-
tions, it is difficult to specify from these
studies which cells were particularly
responsible for removing the residual
anti-myeloblastic activity. However, fail-
ure to absorb activity with spleen militates
against this activity being on a mature
myeloid cell. The low level of cytotoxicity
induced against marrow cells by the 17
final antisera, before their absorption
with marrow, suggests that the absorbing
antigen in marrow is on a minority of
cells. The antisera which showed most
residual activity against AML blasts
after spleen tissue absorption were pro-
duced: (1) following modification of the
immunizing cells with neuraminidase-
treatment of NABS-coating, or (2) by
immunization of animals in which in-
duction of tolerance against normal anti-
gens had been attempted. Detection of
these antigens may be useful for diagnostic
purposes, and could help in distinguishing
variants of the acute myeloblastic leukae-
mias. At the moment we are attempting to
identify the nature of the normal marrow
cells which show antigens common with
leukaemic myeloblast but not found in
splenic tissue. WVe hope that the antisera
absorbed with spleen will help to provide
markers for the physiological stages of
myeloid differentiation.
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One of the most striking positive
findings in this study has been the high
level of reactivity of antisera against
allo-antigens. To some extent this may
reflect the use of the K-cell cytotoxicity
assay. This assay measures IgG antibody
(MacLennan, 1972) whereas complement-
dependent cytolysis is activated more
efficiently on a molar basis by IgM than
IgG (Humphrey, 1967; Linscott, 1970).
The early screening of absorbed antisera
in this study included complement-de-
pendent as well as K-cell-dependent
cytolysis. However, use of the former was
discontinued after the second spleen cell
absorption, as nearly all complement-
revealed activity had been lost at that
stage (Tupchong, 1978). Rabbits have
been used previously to raise antibody
against human polymorphic antigens
(Einstein et al., 1971), but, it does seem
that further use of the rat K-cell assay
for detecting xeno-antibodies against
human HL-A antigens may be profitable.
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